EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Oral Bioavailability Enhancement of Anti-Cancer Drugs Through Lipid Polymer Hybrid Nanoparticles

Saud Almawash iD

Pharmaceutics · 17.03.2025 · 17 (3) · 381

DOI: 10.3390/pharmaceutics17030381 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 17.03.2025. Verfasst von Saud Almawash. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmacy, Shaqra University, Shaqra 11961, Saudi Arabia. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer is considered as the second leading cause of death worldwide. Chemotherapy, radiotherapy, immunotherapy, and targeted drug delivery are the main treatment options for treating cancers. Chemotherapy drugs are either available for oral or parenteral use. Oral chemotherapy, also known as chemotherapy at home, is more likely to improve patient compliance and convenience. Oral anti-cancer drugs have bioavailability issues associated with lower aqueous solubility, first-pass metabolism, poor intestinal permeability and drug absorption, and degradation of the drug throughout its journey in the gastrointestinal tract. A highly developed carrier system known as lipid polymer hybrid nanoparticles (LPHNs) has been introduced. These nanocarriers enhance drug stability, solubility, and absorption, and reduce first-pass metabolism. Consequently, this will have a positive impact on oral bioavailability enhancement. This article provides an in-depth analysis of LPHNs as a novel drug delivery system for anti-cancer agents. It discusses an overview of the limited bioavailability of anti-cancer drugs, their reasons and consequences, LPHNs based anti-cancer drug delivery, conventional and modern preparation methods as well as their drug loading and entrapment efficiencies. In addition, this article also gives an insight into the mechanistic approach to oral bioavailability enhancement, potential applications in anti-cancer drug delivery, limitations, and future prospects of LPHNs in anti-cancer drug delivery.

Schlagwörter

Stichwörter der Autor:innen

anti-cancer drug deliverylimited bioavailabilitylipid polymer hybrid nanoparticles (LPHNs)oral bioavailability enhancementoral chemotherapy

Autor:innen und Institutionen

  • Department of Pharmaceutics, College of Pharmacy, Shaqra University, Shaqra 11961, Saudi Arabia.

ORCID-Profile: Saud Almawash

Zitieren

APA

Almawash, S. (2025). Oral Bioavailability Enhancement of Anti-Cancer Drugs Through Lipid Polymer Hybrid Nanoparticles. Pharmaceutics, 17(3), 381. https://doi.org/10.3390/pharmaceutics17030381

Vancouver

Almawash S. Oral Bioavailability Enhancement of Anti-Cancer Drugs Through Lipid Polymer Hybrid Nanoparticles. Pharmaceutics. 2025;17(3):381. doi:10.3390/pharmaceutics17030381

BibTeX
@article{Almawash2025,
  author = {Almawash, Saud},
  title = {Oral Bioavailability Enhancement of Anti-Cancer Drugs Through Lipid Polymer Hybrid Nanoparticles},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {3},
  pages = {381},
  doi = {10.3390/pharmaceutics17030381}
}
Kostenlos starten →